Insulin-like growth factor-I (IGF-I) is a peptide growth factor that exerts mitogenic and metabolic activities that are regulators of growth, survival and cell differentiation in a number of cell and tissue types. A number of epidemiologic studies have shown a direct association between circulating IGF-I levels and breast cancer risk, especially in young women ([Peyrat *et al*, 1993](#bib33){ref-type="other"}; [Bruning *et al*, 1995](#bib4){ref-type="other"}; [Bohlke *et al*, 1998](#bib3){ref-type="other"}; [Hankinson *et al*, 1998](#bib13){ref-type="other"}; [Toniolo *et al*, 2000](#bib44){ref-type="other"}; [Muti *et al*, 2002](#bib30){ref-type="other"}; [Yu *et al*, 2002](#bib52){ref-type="other"}). Elevated circulating IGF-I also has been found to be a potential cancer risk factor for cancers of other organs, such as the prostate ([Mantzoros *et al*, 1997](#bib27){ref-type="other"}; [Chan *et al*, 1998](#bib5){ref-type="other"}; [Wolk *et al*, 1998](#bib50){ref-type="other"}; [Stattin *et al*, 2000](#bib40){ref-type="other"}) and the colorectum ([Ma *et al*, 1999](#bib26){ref-type="other"}; [Giovannucci *et al*, 2000](#bib10){ref-type="other"}; [Kaaks *et al*, 2000](#bib23){ref-type="other"}; [Palmqvist *et al*, 2002](#bib31){ref-type="other"}).

Most of the circulating IGF-I originates from the liver. In the circulation, it is either free or bound to one of six high-affinity binding proteins, which regulate IGF-I activity. About 90% of the circulating IGF-I is bound to insulin-like binding protein-3 (IGFBP-3), which forms a ternary complex with an acid-labile subunit (ALS). The smaller complexes are able to pass the vascular endothelial barrier and therefore may be important modulators of IGF-I activity at the cellular level ([Jones *et al*, 1993](#bib19){ref-type="other"}; [Rajaram *et al*, 1997](#bib35){ref-type="other"}). There is physiologic evidence of a role for IGFBPs to work either in an IGF-I-dependent, such as increasing the half-life of IGF-I and modulating access to the IGF-I receptor, or IGF-I-independent fashion by mediating their effects directly on target cells, where they generally have a proapoptotic role ([Jones *et al*, 1993](#bib19){ref-type="other"}; [Perks *et al*, 1999](#bib32){ref-type="other"}; [Gleeson *et al*, 2001](#bib11){ref-type="other"}; [Mohan and Baylink, 2002](#bib29){ref-type="other"}).

While nutrition is an important determinant of circulating IGF-I levels ([Thissen *et al*, 1994](#bib43){ref-type="other"}; [Kaaks and Lukanova, 2001](#bib21){ref-type="other"}), heritability studies have shown that up to 40--60% of the variation in circulating IGF-I levels is determined by genetic factors ([Harrela *et al*, 1996](#bib14){ref-type="other"}; [Verhaeghe *et al*, 1996](#bib47){ref-type="other"}; [Hong *et al*, 1997](#bib16){ref-type="other"}; [Hall *et al*, 1999](#bib12){ref-type="other"}). So far, however, only few studies have been conducted to identify specific gene variants that influence circulating IGF-I levels, even though such research is currently intensifying ([Hasegawa *et al*, 2000](#bib15){ref-type="other"}; [Lopez-Bermejo *et al*, 2000](#bib25){ref-type="other"}; [Jernstrom *et al*, 2001a](#bib17){ref-type="other"}; [Vaessen *et al*, 2001](#bib46){ref-type="other"}).

For the present study, we focused on 23 common single nucleotide polymorphisms (SNPs) that we estimated would have the highest chance of having an impact on either the expression or function of IGF-I and of molecules (IGFBP-1, IGFBP-3 and IGFALS) involved in IGF-I transport. We conducted a case--control study of 807 breast cancer patients and 1588 matched control subjects, nested within the cohorts of the European Prospective Investigation into Cancer and Nutrition (EPIC) ([Riboli *et al*, 2002](#bib36){ref-type="other"}; [Bingham and Riboli, 2004](#bib2){ref-type="other"}), and examined relationships of these polymorphisms with circulating IGF-I and IGFBP-3 levels, as well as breast cancer risk.

MATERIAL AND METHODS
====================

The EPIC study
--------------

The EPIC cohort consists of about 370 000 women and 150 000 men, aged 35--69 years, recruited between 1992 and 1998 in 23 research centres in 10 Western European countries. Although detailed information on ethnicity of EPIC subjects is not available, in practice, recruitment has not been conducted in large cosmopolitan urban areas; therefore, owing to the current ethnic composition of the regions involved in the study, we estimate that the vast majority (\>97%) of subjects recruited in the EPIC cohort are of Caucasian origin. All EPIC study subjects provided anthropometric measurements (height, weight, waist and hip circumferences) and extensive, standardised questionnaire information about medical history, diet, physical activity, smoking and other lifestyle factors. Women also answered questions about menstrual and reproductive history, hysterectomy, ovariectomy and use of exogenous hormones for contraception or treatment of menopausal symptoms. In addition, about 240 000 women and 140 000 men provided a blood sample.

Cases of cancer occurring after recruitment into the cohort are identified through local and national cancer registries in seven of the 10 countries, and in France, Germany and Greece by a combination of contacts with national health insurances and/or active follow-up through the study subjects or their next of kin. Follow-up on vital status, to monitor the population remaining at risk for cancer, is achieved through record linkage with mortality registries. In all EPIC study centres, cancer diagnosis is confirmed through comprehensive review of pathology reports, and checks for completeness of follow-up are made periodically. A fully detailed description of the EPIC study has been published elsewhere ([Riboli *et al*, 2002](#bib36){ref-type="other"}; [Bingham and Riboli, 2004](#bib2){ref-type="other"}).

Selection of case and control subjects
--------------------------------------

Cases and controls from the present study were from 16 of the 23 EPIC recruitment centres, in seven of the 10 countries participating in EPIC (UK, Germany, The Netherlands, France, Spain, Italy and Greece), and were part of a larger nested case--control study on serum hormones and breast cancer risk, reported in detail elsewhere ([Kaaks *et al*, 2005a](#bib20){ref-type="other"}, [2005b](#bib22){ref-type="other"}; Rinaldi *et al*, manuscript submitted).

Case subjects were selected among women who developed breast cancer after their recruitment into the EPIC study, and before the end of the study period, for each study centre defined by the latest end-date of follow-up. Women who used any hormone replacement therapy at the time of blood donation, or any exogenous hormones for contraception or medical purposes, and who had previous diagnosis of cancer (except non-melanoma skin cancer) were excluded from the study, because each of these various factors could have altered circulating hormone levels.

For each case subject with breast cancer, two control subjects were chosen at random from among cohort members alive and free of cancer (except non-melanoma skin cancer) at the time of diagnosis of the index case. Control subjects were matched to the cases by study centre where the subjects were enrolled in the cohort, as well as by menopausal status (premenopausal, postmenopausal, perimenopausal/undefined), age (±6 months) at enrolment, follow-up time, fasting status, time of the day of blood donation and phase of the menstrual cycle for premenopausal women (assessed according to criteria defined by Kaaks *et al*).

Approval for the study was given by the relevant Ethical Committees, both at the IARC and in each of the EPIC recruitment centres.

Identification and selection of SNPs
------------------------------------

We collected data on polymorphisms from publicly available databases, such as dbSNP (<http://www.ncbi.nlm.nih.gov/SNP/>), SNPper (<http://snpper.chip.org/>) and Frequency Finder (<http://bluegenes.bsd.uchicago.edu/frequencyfinder/>). We complemented database searches with literature review and, for *IGFBP1* and *IGFBP3*, with analysis of 95 subjects from the EPIC population by denaturing high-performance liquid chromatography (DHPLC; [Xiao and Oefner, 2001](#bib51){ref-type="other"}).

To be included in the study, polymorphisms had to be located in exons (including untranslated regions), exon--intron junctions or promoter regions of a gene of interest, or otherwise should be within intronic regions that showed greater than 80% homology between human and mouse (as reported by the UCSC Genome Browser, <http://genome.ucsc.edu/>), and thus were likely to harbour regulatory sequences. We included only polymorphisms whose existence in Caucasians is documented, either according to literature data or to our own experimental analysis by DHPLC. All new SNPs identified in our laboratory by DHPLC searches have been deposited in dbSNP (<http://www.ncbi.nlm.nih.gov/SNP>). Among all polymorphisms thus identified, we retained only those with a minor allele frequency ⩾5% in Caucasians or those that result in an amino-acid change and had a minor allele frequency ⩾1%. Finally, we particularly favoured the inclusion of all polymorphisms that were previously reported in the literature to be associated with cancer risk and/or levels of circulating hormones. In total, this strategy led to a list of 26 SNPs for genotyping.

Genotyping
----------

Buffy coat samples for the study subjects were retrieved from the EPIC biorepository and DNAs were extracted on an Autopure instrument (Gentra Systems, Minneapolis, MN, USA) with Puregene chemistry (Gentra Systems, Minneapolis, MN, USA).

Genotyping was performed by the 5′ nuclease assay (TaqMan). The order of DNAs from cases and controls was randomised on PCR plates in order to assure that an equal proportion of cases and controls could be analysed simultaneously. TaqMan probes were synthesised by either Applied Biosystems, Foster City, CA, USA (with MGB chemistry) or Proligo, Paris, France (with or without LNA chemistry). Sequences of primers and probes are reported in [Supplementary Table 1](#sup1){ref-type="other"}. For one SNP, a genotyping assay could not be designed and for two more SNPs, TaqMan assays were generated but provided poor genotyping results. This left 23 polymorphisms that were genotyped on the DNAs of cases and controls ([Table 1](#tbl1){ref-type="table"}). The reaction mix included 10 ng genomic DNA, 5 pmol of each primer, 1 pmol of each probe and 2.5 *μ*l of 2 × master mix (Applied Biosystems) in a final volume of 5 *μ*l. The thermocycling included 50 cycles with 30 s at 95°C followed by 60 s at 60°C. PCR plates were read on an ABI PRISM 7900HT instrument (Applied Biosystems). Laboratory personnel was kept blinded to case--control status throughout the study. Genotyping call rates ranged between 95.27 and 99.44%. The distributions of genotypes of all polymorphisms were in agreement with the Hardy--Weinberg equilibrium (calculated in the control group). Repeated quality control genotypes (8% of the total) showed greater than 99% concordance for all assays.

Hormone measurements
--------------------

Measurements of IGF-I and IGFBP-3 were performed in the laboratory of the Hormones and Cancer, at IARC, using enzyme-linked immunosorbent assays from Diagnostic System Laboratories (DSL, Webster, TX, USA). The IGF-I assays included an acid--ethanol precipitation step to eliminate IGF-I binding proteins, to avoid their interference with the IGF-I measurement. Measurements were performed on never thawed serum sample aliquots. The mean intra- and inter-batch coefficients of variation were 6.2 and 16.2% respectively for IGF-I, and 7.2 and 9.7% respectively for IGFBP-3.

Statistical analysis
--------------------

Individual haplotype frequencies (i.e. estimated numbers of copies of haplotypes) were reconstructed using the program 'tagSNPs\' (<http://www-rcf.usc.edu/~stram/tagSNPs.html>; [Stram *et al*, 2003a](#bib41){ref-type="other"}, [2003b](#bib42){ref-type="other"}). This program calculates, for each individual, the expected numbers of copies ('dosages\') of each of the haplotypes compatible with the individuals\' SNP genotypes. This method takes into account uncertainties in the haplotype reconstruction for individuals who are heterozygous for two or more of the SNPs within a given gene. Haplotype dosages are estimated from the individuals\' SNP genotype data and from overall haplotype frequency estimates for the full study population (cases and controls combined) estimated by a maximum likelihood method. For each haplotype, the dosage values range from 0 to 2.0 (alleles), and for each individual these dosage values add up to a total value of 2.0 across all possible haplotypes.

All association analyses, at the level of individual SNPs or gene loci, were performed under different assumed modes of inheritance of effect -- dominant, recessive or codominant -- associated with alleles. In the 'dominant\' model, circulating peptide levels or disease risks were compared between subjects carrying at least one copy of the rare allele and those who had none; in the 'recessive\' model, the comparison was between those who were homozygous for the rare allele and all others; in the 'codominant\' model, individuals\' peptide levels or the logarithm of disease risk were linearly related to the number of copies of an allele (0, 1 or 2 for SNP alleles, or dosages for the haplotype) carried by the individuals. For rare alleles, with a frequency less than 20% (i.e. a prevalence of homozygous recessive allele carriers less than 4%), only the dominant model was used. To test whether any association of gene variants with breast cancer risk could be mediated by alterations in circulating levels of IGF-I and/or IGFBP-3, these associations were also estimated with adjustment for serum peptide levels.

Relationships of polymorphic gene variants with serum levels of IGF-I and IGFBP-3 were estimated by standard normal regression models, stratified by EPIC recruitment centre and further adjusted for age. Relationships of polymorphic variants with breast cancer risk (odds ratios) were estimated using conditional logistic regression models, applied on the matched case--control sets. Both series of analyses were performed at the level of single SNP loci, as well as at the level of haplotypes (using the haplotype dosage values). Haplotype analyses were performed at the level of full gene loci -- that is, including haplotypes based on all of the SNPs in that gene -- and for the *IGF1* and *IGFBP3* genes also at the level of well-delineated haplotype blocks within a gene. In all haplotype analyses, the most common haplotype was used as the reference category.

Adjustment for potentially relevant variables (body mass index, adult height, total caloric intake) did not alter significantly the results (data not shown). Exclusion of cases diagnosed within a year of blood collection also did not have an impact on the results (data not shown).

Reconstruction of haplotype blocks within each gene was performed with Haploview (<http://www.broad.mit.edu/personal/jcbarret/haploview>; [Barrett *et al*, 2005](#bib1){ref-type="other"}). Block boundaries were determined using the criterion of [Gabriel *et al* (2002)](#bib9){ref-type="other"}.

Subgroup analyses on women with a breast cancer diagnosis either before (45% of the subjects) or after age at diagnosis of 55 years (the age at which over 99% of women enrolled in the EPIC cohort declared themselves menopausal) were used to examine whether associations of gene variants with breast cancer risk differed between women with cancer at approximately premenopausal or postmenopausal age, and possible heterogeneity of effect between these two age groups was tested using a χ^2^ test.

We estimated the false positive reporting probability (FPRP) for statistically significant observations based on the methods described by [Wacholder *et al* (2004)](#bib48){ref-type="other"}. Prior probability is likely to be influenced by the biological knowledge of the gene, the functional significance of the variants and the available epidemiological evidence. It remains a subjective measure that may vary from one investigator to another based on the importance they assign to the different pieces of evidence. For this reason, we have calculated FPRP for a range of prior probabilities from 50 to 0.1%. We considered that a prior probability of 50% might be acceptable when there was a very strong biological plausibility with consistent epidemiological evidence (i.e. the association between SNPs in the 5′ part of *IGFBP3* and IGFBP-3 level), and a prior probability of 0.1% may be appropriate when the biological knowledge and epidemiological data were both inadequate (i.e. the majority of other SNPs, whose exact function is not known, and epidemiological data do not exist).

RESULTS
=======

A total of 807 incident cases of breast cancer from the EPIC cohort and 1588 matched controls were included in our study. The mean age of study subjects at blood donation was 55 years (5th--95th percentile: 39.9--68.7 years). For cases, the mean age at diagnosis was 57 years (5th--95th percentile: 42--71 years). Based on the questionnaire data, 32% of the subjects were premenopausal at blood donation, 10% were perimenopausal or of unknown menopausal status and 58% were postmenopausal. Cases had a significantly lower number of full-term pregnancies than controls (means: 2.35 *vs* 2.47, *P*=0.02) and were significantly older at first full-term pregnancy (26 *vs* 25.5 years in controls, *P*=0.02). Age at menarche did not differ between cases and controls, nor did body mass index. Serum levels of IGF-I adjusted for age and centre were not significantly different between cases and controls (means: 248.7 *vs* 244.4 ng ml^−1^, *P*=0.15), nor for the subgroups subjects with cancer diagnosis before or at the age of 55 years (272.0 *vs* 270.7; *P*=0.79), or after (224.0 *vs* 217.5; *P*=0.08). Case subjects did show higher mean levels of serum IGFBP-3 than controls (means: 3422 *vs* 3361 ng ml^−1^, *P*=0.04). The latter difference, however, was due mostly to the subgroup with cancer diagnosis after age 55 years (3473 *vs* 3378; *P*=0.02), and was not clearly visible among the younger women (3190 *vs* 3173; *P*=0.66). Details on the relationships of IGF-I and IGFBP-3 with breast cancer risk, with an extended series of 1195 beast cancer cases and 2321 control subjects, will be reported elsewhere (Rinaldi *et al*, manuscript submitted).

The number of SNPs typed per gene ranged from three for *IGFALS* to eight for *IGFBP3*. Results of associations between individual SNPs and cancer risk and circulating IGF-I and IGFBP-3 levels are reported in [Table 2](#tbl2){ref-type="table"}. [Supplementary Tables 2a--f](#sup1){ref-type="other"} report results of analyses relating hormone levels and breast cancer risk to haplotypes.

In the *IGF1* gene, we noted an association of the rs2162679 SNP, with the G/G genotype being associated with a reduction in risk of breast cancer (*P*=0.05) and also a modest effect in the heterozygote (*P*-trend for codominant model=0.03). Interestingly, when the cases were stratified by age of onset (less than 55 years old or greater than or equal to 55 years old), this reduction appears to be confined to breast cancer cases with an early age of diagnosis, at 55 years or before, and was strongest (odds ratio 0.17, confidence interval 0.07--0.56) in the homozygous G/G (*P*=0.005). This association was also found to be statistically significant under the dominant (*P*=0.01) and codominant (*P*=0.002) models. Linkage disequilibrium (LD) reconstruction of this region shows that there is strong LD between the rs2162679 and the two surrounding SNPs, rs35765 and rs35767. As expected, rs35767 and rs35765 also showed a reduction in breast cancer risk among the entire set, although the only statistically significant result was seen for rs35767 when testing for trend (*P*=0.04). However, as with rs2162679, the reduction effect was statistically significant in both rs35767 and rs35765 for the breast cancer cases diagnosed at age 55 years or before. Haplotype analysis of the *IGF1* data showed only an association between one rare haplotype and cancer risk ([Supplementary Table 2](#sup1){ref-type="other"}). When we analysed the block structure of *IGF1*, based on our control genotypes, we noted a clear haplotype block that contains rs35765, rs35767 and rs2162679 ([Figure 1A](#fig1){ref-type="fig"}). When we restricted our haplotype analysis to only this block, we observed an association between cancer risk and haplotype hCTG, which has a frequency of 4% and includes the rare alleles of rs35767 and rs2162679. This association was not stronger than that seen with the individual SNPs ([Supplementary Table 2](#sup1){ref-type="other"}).

We also noted a significant decrease in circulating IGFBP-3 levels with the rare homozygous states for both rs2162679 and rs35767 (again representing the LD between these markers). In contrast to the association of breast cancer risk, with the same markers, this effect appeared restricted to a later age of onset in our age-stratified analysis. When we performed the same analysis by using the haplotype block that spans the 5′ end of the gene and includes rs2162679 and rs35767, the same haplotype that is associated with reduced cancer risk appeared also to be strongly associated with decreased IGFBP-3 levels (*P*\<0.0001). The only other result of interest in the *IGF1* gene was a relatively modest dominant effect of polymorphisms rs35765, rs35767 and rs6220, resulting in a higher mean circulating IGF-I level, and visible also in the haplotype analysis.

For the *IGFBP3* gene, we observed that a number of previous studies showed an increase in circulating IGFBP-3 levels associated with the A allele of a polymorphism in the promoter of *IGFBP3* at position −202 (rs2854744) (*P*⩽0.0001). Reflecting the strong amount of LD in this area ([Figure 1B](#fig1){ref-type="fig"}), we also noted a strong association between increased IGFBP-3 levels and alleles of the surrounding polymorphisms, rs2132571, rs2132572, rs2471551, which belong to the same haplotype block ([Supplementary Table 2](#sup1){ref-type="other"}).

The polymorphism P0453 of *IGFBP3* also showed a slight increase in the mean circulating IGF-I protein levels and one *IGFBP3* haplotype showed an increase in risk of breast cancer, under a recessive model.

Polymorphic variations in the *IGFBP1* gene did not show associations with any of the end points. Homozygous carriers of the polymorphism rs3751893 in *IGFALS*, however, showed a significant reduction in mean circulating IGF-I levels.

DISCUSSION
==========

We have performed a large-scale association study, nested in the EPIC cohort, to assess the role of genetic variation of *IGF1* and of the genes encoding the major IGF-I binding proteins on risk of breast cancer and on circulating levels of IGF-I and IGFBP-3. We genotyped 23 SNPs in the four candidate genes. Our criteria for selecting the SNPs to study were proven existence in the Caucasian population, high allele frequency and/or high chance of having an impact on gene expression or function of the gene product. Our selection of SNPs to be typed was not based on a formal haplotype tagging approach, because we estimated that the available information (as of the time of writing this report) was insufficient to do so accurately. In view of the relative paucity of publicly available (e.g. HapMap) data, an accurate haplotype tagging approach would have required complete resequencing of the gene region in a sufficient number of subjects, in order to establish a complete catalogue of polymorphisms and to examine LD patterns between them. Such effort was beyond the scope of the present project. Nevertheless, we feel that it is unlikely that many new common polymorphisms, which were the focus of our investigation, would have been discovered by systematic resequencing.

The use of a multicentric study raises the possibility of confounding by population stratification. Although 97% of EPIC subjects are estimated to be of Caucasian origin, there could still be confounding by population stratification if SNP or haplotype allele frequencies varied between the subject recruitment areas, while at the same time there was also variation in average breast cancer incidence rates. We did not observe wide differences in allele frequencies between different countries in our study (data not shown). In addition, breast cancer cases and control subjects were systematically matched for the study centre where they had been recruited into the EPIC cohorts, and we adjusted all statistical analyses of association between SNPs, hormone levels and breast cancer risk for the factor 'recruitment centre\'. We believe therefore that confounding by population stratification is not an issue in our study.

We have found an association with decreased breast cancer risk of a haplotype located in the 5′ part of *IGF1*. This association was particularly strong among women younger than 55 years.

No other variant among the ones we studied showed any association with cancer risk, except for two haplotypes of *IGFBP3*. These associations are likely to be chance findings, as they are based on small numbers.

Our results suggest that in none of the four genes we examined were there any SNPs that had a strong impact on circulating levels of IGF-I.

Our results are in conflict with a previous study ([Ukkola *et al*, 2001](#bib45){ref-type="other"}), which found that carriers of the less frequent G variant allele of SNP rs3793344, located in a region of intron 1 of *IGFBP1*, which harbours sequences affecting gene expression, had significantly lower circulating levels of IGF-I both before and after overfeeding. Subjects carrying two copies of the A allele had lower IGF-I concentrations before overfeeding, which were further decreased after overfeeding compared to subjects carrying the rarer G allele. This may indicate that the AA genotype results in higher IGFBP-1 concentrations, which could decrease available IGF-I. We found no evidence of higher IGF-I concentrations with this polymorphism. It is possible that the previously reported association ([Ukkola *et al*, 2001](#bib45){ref-type="other"}) is linked to the peculiar study conditions (long-term caloric surplus). Alternatively, the association could be due to a statistical fluctuation caused by the small sample size of the study (12 pairs of monozygotic twins).

The finding supported by the strongest statistical evidence in our study is the association of polymorphisms in the 5′ region of *IGFBP3* with circulating levels of IGFBP-3. This association has been reported in several previous studies, and has been ascribed to a polymorphism located at position −202 (rs2854744) from the transcription start site ([Deal *et al*, 2001](#bib6){ref-type="other"}; [Jernstrom *et al*, 2001b](#bib18){ref-type="other"}; [Schernhammer *et al*, 2003](#bib38){ref-type="other"}). In accordance with these previous reports, we also found a dose-dependent association of the A allele with increased levels of circulating IGFBP-3. In addition, we observed strong associations of all surrounding polymorphisms with IGFBP-3 levels ([Supplementary Table 2](#sup1){ref-type="other"}). This leads to the question which of these various polymorphisms would be the functional polymorphism causing the association with IGFBP-3 levels. In a recent study *in vitro*, a construct including only the A allele of the rs2854744 SNP variant was found to increase promoter activity, suggesting that rs2854744 is the functional variant that affects IGFBP-3 transcription, and that the associations we have observed with the other polymorphisms of *IGFBP3* are exclusively due to strong LD ([Deal *et al*, 2001](#bib6){ref-type="other"}).

The −202 polymorphism also has been studied in relation to risk of breast cancer ([Deal *et al*, 2001](#bib6){ref-type="other"}; [Schernhammer *et al*, 2003](#bib38){ref-type="other"}) and other cancers ([Wang *et al*, 2003](#bib49){ref-type="other"}; [Li *et al*, 2004](#bib24){ref-type="other"}; [Slattery *et al*, 2004](#bib39){ref-type="other"}). In agreement with most previous studies, we noted no association between this allele in our series as a whole, or in our stratified analysis based on age of onset. Probably, the effect of this polymorphism on circulating IFGBP-3 levels (estimated in 6--9% of variation) ([Jernstrom *et al*, 2001b](#bib18){ref-type="other"}; [Schernhammer *et al*, 2003](#bib38){ref-type="other"}) is not sufficient, by itself, to alter amounts of bioavailable IGF-I sufficiently to lead to a substantial change in cancer risk. In one recent study, however, the C allele of the −202 polymorphism was found to be associated with more advanced disease status in prostate cancer, even though it was not associated with prostate cancer risk overall ([Wang *et al*, 2003](#bib49){ref-type="other"}).

Besides polymorphic variation in the *IGFBP3* gene, another strong predictor of variability in IGFBP-3 levels was the same *IGF1* haplotype that was associated, in the same direction, with cancer risk. This was particularly evident when the analysis was restricted to the haplotypes observed within the strong LD block in the 5′ region of the gene. It is difficult to interpret these associations, with either IGFBP-3 levels or cancer risk, as for none of these SNPs is there any evidence to suggest a possible functional role. Little appears to be known about what genomic elements are involved in the regulation of *IGF1* transcription, except for a region immediately upstream of the transcription start ([Porcu *et al*, 1994](#bib34){ref-type="other"}; [Rubini *et al*, 1994](#bib37){ref-type="other"}), which however harbours no known genetic variation. We have not typed a CA repeat polymorphism located in the 5′ region of *IGF1*, between SNPs rs35767 and rs2162679, which has been frequently included in previous studies. Several epidemiological studies on the association between this polymorphism and breast cancer risk or IGF-I levels ([Jernstrom *et al*, 2001a](#bib17){ref-type="other"}; [Yu *et al*, 2001](#bib53){ref-type="other"}; [Figer *et al*, 2002](#bib8){ref-type="other"}; [Missmer *et al*, 2002](#bib28){ref-type="other"}; [DeLellis *et al*, 2003](#bib7){ref-type="other"}) have yielded highly conflicting results. This microsatellite polymorphism has a large number of alleles, which results in fractioning the study population into a large number of classes. Even with a large sample size, this makes statistical analysis very difficult. Moreover, there are no studies that show a functional role for this microsatellite. We believe that it is unlikely that the *IGF1* CA repeat has a functional role of its own, and that associations previously reported with this microsatellite are likely to reflect LD with the same SNPs that we included in our study or with other, yet unknown SNPs located in the region. In any case, the level of LD in the 5′ region of the gene is so high that an association study approach alone will not be able to single out one particular variant as that causing variation in IGFBP-3 levels and, possibly, cancer risk. Moreover, genetic variation in the promoter of *IGF1* should have an impact on circulating IGFBP-3 only through a modification of circulating IGF-I, which we observe only at modest levels. Functional studies will be needed to clarify this point.

Other polymorphic variants that were found to be associated with IGFBP-3 levels -- a haplotype in the 5′ region of *IGF1*, in homozygosity, and SNP rs3751893 of *IGFALS* -- are difficult to evaluate, because of the small number of subjects carrying the alleles that showed the associations.

In summary, the main findings of our study were thus a weak but nominally significant association of a block of polymorphisms located at the 5′ end of the *IGF1* gene with breast cancer risk, particularly among women younger than 55 years, and an association of polymorphisms located in the 5′ region of *IGFBP3* with circulating levels of IGFBP-3. The large number of statistical tests we have performed raises the issue of potential false positives. An alternative to applying a Bonferroni\'s correction, which is generally too conservative because of statistical dependence between tests for multiple SNPs that are in LD, is the use of a Bayesian approach, such as the recently introduced calculation of FPRP ([Wacholder *et al*, 2004](#bib48){ref-type="other"}). Given the absence of previous functional or epidemiologic data on the *IGF1* SNPs we found associated with breast cancer risk, we calculated FPRPs by using a prior probability of true association. Calculated FPRPs were high even with a relatively high prior probability of 0.01 that variants would have an association with breast cancer risk or with circulating peptide levels. Our finding relating *IGFBP3* SNPs with serum IGFBP-3 levels, however, is strongly backed by previous epidemiologic and functional findings and is also supported by very low *P*-values in our study, and resulted in very low FPRPs over a wide range of prior probabilities of true association.

In conclusion, our results show a number of genetic variants associated with circulating hormone levels, including a convincing association of *IGFBP3* SNPs with IGFBP-3 levels. On the other hand, we have found only weak or no associations of genetic variants in *IGF1*, *IGFBP1*, *IGFBP3* and *IGFALS* with breast cancer risk, and further large studies will be required to confirm our findings.
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![(**A**) Graphical representation of LD and block structure of *IGF1*. (**B**) Graphical representation of LD and block structure of *IGFBP3*. The upper bars represent SNPs and physical distances among them. Numbers within squares are pairwise *D*′ values. Absence of value means *D*′=1. The colour code shows confidence boundaries of LD estimations: black shows evidence of LD, white shows evidence of recombination and grey shows uninformative pairs. Linkage disequilibrium blocks were defined according to the algorithm of [Gabriel *et al* (2002)](#bib9){ref-type="other"}. Internal references are used for polymorphisms not present in dbSNP.](94-6602936f1){#fig1}

###### 

Polymorphisms used in the present study

  **Polymorphism^a^**    **Alleles (major\>minor)**   **Position in gene**   **Codon**
  --------------------- ---------------------------- ---------------------- -----------
  *IGF1*                                                                    
  rs35765                           C\>A                Promoter region           
  rs35767                           C\>T                Promoter region           
  rs2162679                         A\>G                    Intron 1              
  rs6220                            T\>C                 Exon 4; 3′ UTR           
  rs6214                            C\>T                 Exon 4; 3′ UTR           
                                                                            
  *IGFBP1*                                                                  
  rs1995051                         G\>A                Promoter region           
  rs1065780                         G\>A                Promoter region           
  rs9658194                         C\>A                    Intron 1              
  rs3828998                         T\>C                    Intron 1              
  rs3793344                         A\>G                    Intron 1              
  rs4988515                         C\>T                     Exon 4          Cys230Cys
  rs4619                            A\>G                     Exon 4          Met253Ile
                                                                            
  *IGFBP3*                                                                  
  rs2132571                         G\>A                Promoter region           
  rs2132572                         G\>A                Promoter region           
  rs2854744                         C\>A                Promoter region           
  rs2471551                         G\>C                    Intron 1              
  P0453^b^                          C\>T                     Exon 4          Thr277Ile
  rs2453839                         A\>G                 Exon4; 3′ UTR            
  P0448^b^                          T\>C                 Exon4; 3′ UTR            
  rs6670                            A\>T                 Exon4; 3′ UTR            
                                                                            
  *IGFALS*                                                                  
  rs3751893                         T\>C                     Exon 2          Asp70Asp
  rs17559                           C\>T                     Exon 2          Tyr462Tyr
  rs2230053                         G\>A                     Exon 2          Thr522Thr

UTR=untranslated region.

Polymorphisms are identified by their dbSNP accession number.

Internal references are used for polymorphisms not present in dbSNP.

###### 

Associations between SNPs and breast cancer risk and mean IGF-I and IGFBP-3 levels adjusted for age and centre

                                           **Genotype**                                                                        
  ---------- ----------- ---------------- -------------- ------------------- ------------------- -------------- -------------- --------------
  *IGF1*       rs35765   Cases/controls      609/1148          169/362              17/37                                       
                         OR (95% CI)           1.00       0.88 (0.72--1.08)   0.86 (0.48--1.54)  0.22           0.21           0.70
                         Mean IGF-I           244.2             253.6               234.4        0.10           **0.02**       0.21
                         Mean IGFBP-3          3379             3412                3371         0.46           0.36           0.87
                                                                                                                               
               rs35767   Cases/controls      549/1016          201/432              22/62                                       
                         OR (95% CI)           1.00       0.86 (0.71--1.05)   0.66 (0.40--1.09)  **0.04**       0.07           0.15
                         Mean IGF-I           243.2             252.0               238.0        0.10           **0.02**       0.32
                         Mean IGFBP-3          3377             3385                3204         0.25           0.66           **0.02**
                                                                                                                               
              rs2162679  Cases/controls      570/1060          212/446              19/61                                       
                         OR (95% CI)           1.00       0.88 (0.72--1.06)   0.57 (0.34--0.97)  **0.03**       0.07           0.05
                         Mean IGF-I           244.7             251.5               239.3        0.23           0.08           0.35
                         Mean IGFBP-3          3397             3382                3165         **0.04**       0.20           **0.003**
                                                                                                                               
               rs6220    Cases/controls      405/813           325/592             59/126                                       
                         OR (95% CI)           1.00       1.11 (0.92--1.33)   0.95 (0.68--1.32)  0.69           0.39           0.54
                         Mean IGF-I           247.6             255.2               247.0        0.17           **0.03**       0.46
                         Mean IGFBP-3          3420             3395                3363         0.22           0.26           0.38
                                                                                                                               
               rs6214    Cases/controls      282/503           366/753             131/271                                      
                         OR (95% CI)           1.00       0.88 (0.72--1.06)   0.88 (0.68--1.13)  0.22           0.15           0.64
                         Mean IGF-I           246.7             244.3               244.9        0.56           0.45           0.91
                         Mean IGFBP-3          3395             3344                3376         0.41           0.15           0.79
                                                                                                                               
  *IGFALS*    rs3751893  Cases/controls      546/1085          231/436              21/42                                       
                         OR (95% CI)           1.00       1.06 (0.88--1.28)   0.98 (0.57--1.67)  0.67           0.59           0.89
                         Mean IGF-I           251.4             249.8               226.4        0.06           0.23           **0.005**
                         Mean IGFBP-3          3420             3375                3305         0.07           0.10           0.24
                                                                                                                               
               rs17559   Cases/controls      620/1246          149/256              5/10                                        
                         OR (95% CI)           1.00       1.17 (0.94--1.46)   1.02 (0.35--2.99)  0.19           0.17           1.00
                         Mean IGF-I           244.9             248.5               227.9        0.60           0.45           0.32
                         Mean IGFBP-3          3375             3344                3439         0.53           0.45           0.69
                                                                                                                               
              rs2230053  Cases/controls      788/1551           13/16                0/1                                        
                         OR (95% CI)           1.00       1.64 (0.75--0.36)          ---         0.37           0.28           ---
                         Mean IGF-I           246.2             248.3               240.1        0.90           0.89           0.93
                         Mean IGFBP-3          3385             3487                3751         0.35           0.38           0.59
                                                                                                                               
  *IGFBP1*    rs1995051  Cases/controls      413/766           302/627             60/110                                       
                         OR (95% CI)           1.00       0.89 (0.74--1.07)   1.02 (0.73--1.42)  0.50           0.28           0.67
                         Mean IGF-I           253.4             256.3               247.1        0.89           0.59           0.17
                         Mean IGFBP-3          3239             3243                3261         0.74           0.82           0.71
                                                                                                                               
              rs1065780  Cases/controls      304/555           356/741             114/207                                      
                         OR (95% CI)           1.00       0.88 (0.73--1.07)   1.02 (0.78--1.33)  0.71           0.31           0.50
                         Mean IGF-I           252.9             254.3               255.7        0.52           0.57           0.63
                         Mean IGFBP-3          3234             3260                3210         0.91           0.61           0.35
                                                                                                                               
              rs9658194  Cases/controls      291/521           253/498              25/51                                       
                         OR (95% CI)           1.00       0.98 (0.81--1.19)   0.95 (0.59--1.55)  0.81           0.83           0.87
                         Mean IGF-I           253.5             254.2               253.1        0.88           0.84           0.94
                         Mean IGFBP-3          3222             3281                3264         0.08           0.05           0.78
                                                                                                                               
              rs3828998  Cases/controls      291/521           332/686             110/194                                      
                         OR (95% CI)           1.00       0.87 (0.71--1.05)   1.03 (0.78--1.35)  0.71           0.27           0.42
                         Mean IGF-I           253.7             253.6               255.6        0.75           0.91           0.64
                         Mean IGFBP-3          3198             3214                3183         0.93           0.76           0.56
                                                                                                                               
              rs3793344  Cases/controls      305/549           350/742             115/203                                      
                         OR (95% CI)           1.00       0.85 (0.70--1.02)   1.03 (0.79--1.35)  0.66           0.19           0.34
                         Mean IGF-I           254.0             254.1               255.3        0.82           0.91           0.77
                         Mean IGFBP-3          3233             3256                3212         0.93           0.64           0.41
                                                                                                                               
              rs4988515  Cases/controls      715/1412          62/111                2/6                                        
                         OR (95% CI)           1.00       1.11 (0.80--1.54)   0.67 (0.13--3.30)  0.72           0.62           0.62
                         Mean IGF-I           253.9             258.6               239.9        0.57           0.46           0.56
                         Mean IGFBP-3          3164             3213                3479         0.18           0.25           0.20
                                                                                                                               
               rs4619    Cases/controls      347/665           347/698             89/175                                       
                         OR (95% CI)           1.00       0.95 (0.79--1.15)   0.97 (0.73--1.30)  0.71           0.62           1.00
                         Mean IGF-I           254.2             253.4               257.4        0.70           0.99           0.43
                         Mean IGFBP-3          3174             3171                3124         0.41           0.67           0.28
                                                                                                                               
  *IGFBP3*    rs2132571  Cases/controls      393/714           308/674             75/135                                       
                         OR (95% CI)           1.00       0.83 (0.69--0.99)   1.01 (0.74--1.38)  0.29           0.08           0.50
                         Mean IGF-I           253.5             253.0               256.8        0.73           0.96           0.49
                         Mean IFGBP-3          3322             3208                3034         **\<0.0001**   **\<0.0001**   **\<0.0001**
                                                                                                                               
              rs2132572  Cases/controls      501/980           234/478              42/59                                       
                         OR (95% CI)           1.00       0.96 (0.80--1.17)   1.42 (0.94--2.15)  0.47           0.90           0.08
                         Mean IGF-I           254.2             251.1               274.5        0.30           0.94           **0.002**
                         Mean IFGBP-3          3266             3195                3206         **0.03**       **0.02**       0.61
                                                                                                                               
              rs2854744  Cases/controls      208/407           368/743             200/369                                      
                         OR (95% CI)           1.00       0.97 (0.79--1.20)   1.08 (0.85--1.38)  0.52           0.92           0.34
                         Mean IGF-I           259.8             248.8               254.8        0.19           **0.01**       0.51
                         Mean IFGBP-3          3101             3246                3389         **\<0.0001**   **\<0.0001**   **\<0.0001**
                                                                                                                               
              rs2471551  Cases/controls      485/928           248/508              38/59                                       
                         OR (95% CI)           1.00       0.92 (0.76--1.12)   1.22 (0.80--1.86)  0.97           0.62           0.29
                         Mean IGF-I           252.4             254.0               257.8        0.42           0.50           0.50
                         Mean IFGBP-3          3285             3200                2994         **\<0.0001**   **0.0002**     **0.0002**
                                                                                                                               
              P0453^d^   Cases/controls      770/1506           10/29                ---                                        
                         OR (95% CI)           1.00       0.68 (0.33--1.39)          ---         0.29           0.29           ---
                         Mean IGF-I           253.4             289.5                ---         **0.001**      **0.001**      ---
                         Mean IFGBP-3          3243             3078                 ---         0.13           0.13           ---
                                                                                                                               
              rs2453839  Cases/controls      523/985           236/502              27/59                                       
                         OR (95% CI)           1.00       0.89 (0.74--1.08)   0.87 (0.55--1.39)  0.22           0.20           0.67
                         Mean IGF-I           254.1             253.2               255.0        0.90           0.83           0.87
                         Mean IFGBP-3          3243             3232                3273         0.96           0.81           0.66
                                                                                                                               
              P0448^d^   Cases/controls      566/1116          202/384              14/26                                       
                         OR (95% CI)           1.00       1.05 (0.86--1.29)   1.07 (0.56--2.06)  0.61           0.61           0.87
                         Mean IGF-I           255.0             250.5               245.9        0.13           0.15           0.47
                         Mean IFGBP-3          3233             3272                3270         0.24           0.22           0.80
                                                                                                                               
               rs6670    Cases/controls      445/887           287/572              43/61                                       
                         OR (95% CI)           1.00       1.00 (0.83--1.19)   1.44 (0.95--2.18)  0.35           0.69           0.08
                         Mean IGF-I           260.7             256.4               254.3        0.12           0.12           0.50
                         Mean IFGBP-3          3263             3256                3368         0.48           0.87           0.11

*P*-value for codominant model (trend).

*P*-value for dominant model.

*P*-value for recessive model.

SNP=single nucleotide polymorphism; IGF-I=insulin-like growth factor I; IGFBP-3=insulin-like binding protein-3; OR=odds ratio; CI=confidence interval.

Mean IGF-I and mean IFGBP-3 are means of hormone levels, expressed in ng/ml, for subjects (cases+controls) belonging to each genotype category, adjusted for age and centre.

Internal references are used for polymorphisms not present in dbSNP.

*P*-values that reached statistical significance at the 0.05 level are reported in bold.
